

CITATION REPORT

List of articles citing

Liver injury during antituberculosis treatment: an 11-year study

DOI: 10.1016/s0962-8479(96)90098-2
Tubercle and Lung Disease, 1996, 77, 335-40.

Source: <https://exaly.com/paper-pdf/27295513/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|--|----|-----------|
| 110 | Severe hepatic complications of antituberculous therapy. 1999 , 10, 167-9 | | 2 |
| 109 | Hepatic enzyme abnormalities in children on triple therapy for tuberculosis. 1999 , 27, 37-42 | | 15 |
| 108 | Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. 2003 , 167, 1472-7 | | 565 |
| 107 | American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. 2003 , 167, 603-62 | | 1519 |
| 106 | Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. 2003 , 124, 2112-8 | | 32 |
| 105 | Screening in liver disease: report of an AASLD clinical workshop. 2004 , 39, 1204-12 | | 50 |
| 104 | Antituberculosis drugs and hepatotoxicity. 2004 , 4, 167-70 | | 33 |
| 103 | [When should standard treatment not be applied for the tuberculosis patient?]. 2004 , 21, S75-97 | | 8 |
| 102 | Isoniazid-induced hyperacute liver failure in a young patient receiving carbamazepine. 2004 , 15, 396-397 | | 13 |
| 101 | Inactive Hepatitis B Surface Antigen Carrier State and Hepatotoxicity During Antituberculosis Chemotherapy. 2005 , 127, 1304-1311 | | 3 |
| 100 | Tuberculosis in pregnancy. 2005 , 32, 739-47 | | 17 |
| 99 | The management of respiratory infections during pregnancy. 2006 , 26, 155-72, viii | | 17 |
| 98 | Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. 2006 , 100, 1834-42 | | 89 |
| 97 | Antituberculosis drugs and hepatotoxicity. 2006 , 11, 699-707 | | 172 |
| 96 | Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. 2006 , 42, 346-55 | | 41 |
| 95 | An official ATS statement: hepatotoxicity of antituberculosis therapy. 2006 , 174, 935-52 | | 742 |
| 94 | Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. 2006 , 61, 791-4 | | 100 |

| | | |
|----|--|-----|
| 93 | Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. 2007 , 84, 173-9 | 44 |
| 92 | Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. 2007 , 131, 803-808 | 34 |
| 91 | Treatment of tuberculosis. 2007 , 1, 85-97 | 8 |
| 90 | Idiosyncratic drug reactions: current understanding. 2007 , 47, 513-39 | 243 |
| 89 | Clinical characteristics of tuberculosis in patients with liver cirrhosis. 2007 , 12, 401-5 | 51 |
| 88 | Short communication: antituberculosis drug-induced hepatotoxicity is unexpectedly low in HIV-infected pulmonary tuberculosis patients in Malawi. 2007 , 12, 852-5 | 10 |
| 87 | Liver and pancreatic injury induced by antituberculous therapy. 2007 , 52, 3275-81 | 3 |
| 86 | Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. 2008 , 62, 135-47 | 27 |
| 85 | Hepatotoxicity of pyrazinamide: cohort and case-control analyses. 2008 , 177, 1391-6 | 81 |
| 84 | Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. 2008 , 23, 192-202 | 443 |
| 83 | Treatment of tuberculosis in presence of hepatic and renal impairment. 2008 , 13, S100-S107 | 4 |
| 82 | Tuberculosis and hepatic toxicity in children. 2008 , 2, 463-475 | |
| 81 | Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. 2009 , 29, 1468-81 | 50 |
| 80 | Knowledge, attitudes, and practices of physicians in Tomsk Oblast tuberculosis services regarding alcohol use among tuberculosis patients in Tomsk, Russia. 2009 , 33, 523-37 | 4 |
| 79 | Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. 2009 , 10, 1433-45 | 57 |
| 78 | A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature. 2009 , 108, 102-11 | 24 |
| 77 | Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. 2010 , 17, 17-22 | 38 |
| 76 | Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. 2010 , 10, 524-36 | 43 |

| | | |
|----|---|-----|
| 75 | Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS). 2010 , 10, 267 | 34 |
| 74 | Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis. 2010 , 61, 323-9 | 26 |
| 73 | Integrated Management of Physician-delivered Alcohol Care for Tuberculosis Patients: Design and Implementation. 2010 , 34, 317-30 | 23 |
| 72 | Risk factors for idiosyncratic drug-induced liver injury. 2010 , 138, 2246-59 | 233 |
| 71 | Hepatotoxic effects of therapies for tuberculosis. 2010 , 7, 543-56 | 53 |
| 70 | Hepatic safety of antibiotics used in primary care. 2011 , 66, 1431-46 | 118 |
| 69 | Tuberculosis. 2011 , 577-600 | 3 |
| 68 | Experience with rifabutin replacing rifampin in the treatment of tuberculosis. 2011 , 15, 1485-9, i | 37 |
| 67 | Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity. 2011 , 105, 400-8 | 31 |
| 66 | Alcohol use and the management of multidrug-resistant tuberculosis in Tomsk, Russian Federation. 2012 , 16, 891-6 | 20 |
| 65 | Idiosyncratic Drug Reactions and the Potential Role of Metabolism. 2012 , 1 | |
| 64 | A comparison between two strategies for monitoring hepatic function during antituberculous therapy. 2012 , 185, 653-9 | 34 |
| 63 | NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. 2012 , 16, 589-95 | 66 |
| 62 | Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome. 2012 , 16, 596-603 | 21 |
| 61 | Hepatic dysfunction in children with tuberculosis on treatment with antituberculous therapy. 2012 , 11, 96-99 | 4 |
| 60 | Evaluation of the physicians Approach to the diagnosis and treatment of patients with antituberculosis drug-induced hepatotoxicity. 2012 , 18, 1119-25 | 3 |
| 59 | Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients. 2012 , 92, 253-9 | 44 |
| 58 | Gene expression profiling reveals potential key pathways involved in pyrazinamide-mediated hepatotoxicity in Wistar rats. 2013 , 33, 807-19 | 15 |

| | | |
|----|---|-----|
| 57 | Clinical characteristics and treatment outcomes of tuberculosis in the elderly: a case control study. 2013 , 13, 121 | 28 |
| 56 | Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. 2013 , 28, 1368-74 | 40 |
| 55 | Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. 2013 , 3, 37-49 | 225 |
| 54 | Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. 2013 , 28, 323-8 | 46 |
| 53 | Hepatotoxicity of Antitubercular Drugs. 2013 , 483-504 | 4 |
| 52 | Antitubercular therapy in patients with cirrhosis: challenges and options. 2014 , 20, 5760-72 | 20 |
| 51 | Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis. 2014 , 192, 205-10 | 17 |
| 50 | Mass treatment to eliminate tuberculosis from an island population. 2014 , 18, 899-904 | 6 |
| 49 | Lack of associations between tumor necrosis factor- β genetic polymorphism -308G/A and antituberculous drug-induced maculopapular eruption. 2015 , 3, 124 | 1 |
| 48 | Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity. 2015 , 89, 883-97 | 39 |
| 47 | Incidence and risk factors of major toxicity associated to first-line antituberculosis drugs for latent and active tuberculosis during a period of 10 years. 2015 , 21, 144-50 | 14 |
| 46 | Association of polymorphisms in drug transporter genes (SLCO1B1 and SLC10A1) and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort. 2015 , 95, 68-74 | 14 |
| 45 | Antituberculosis drugs. 2016 , 631-646 | |
| 44 | Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity. 2016 , 11, e0157478 | 16 |
| 43 | Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting. 2016 , 11, e0166030 | 5 |
| 42 | Drug-related hepatitis in patients treated with standard anti-tuberculosis chemotherapy over a 30-year period. 2016 , 20, 1621-1624 | 12 |
| 41 | Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis. 2016 , 20, 800-5 | 11 |
| 40 | Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. 2016 , 16, 50 | 39 |

| | | |
|----|---|----|
| 39 | Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study. 2016 , 5, 14-20 | 35 |
| 38 | Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to anti-tubercular treatment. 2017 , 19, e12658 | 7 |
| 37 | Tuberculosis of the Liver, Biliary Tract, and Pancreas. 2017 , 5, | 6 |
| 36 | Chemotherapy of Tuberculosis. 2017 , 5, | 11 |
| 35 | The Causes and Clinical Spectrum of Drug-Induced Cholestatic Liver Injury. 2017 , 16, 130-136 | |
| 34 | Chemotherapy of Tuberculosis. 2017 , 101-117 | |
| 33 | Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. 2018 , 47, 1213-1219 | 12 |
| 32 | Urgent Living-Donor Liver Transplantation in a Patient With Concurrent Active Tuberculosis: A Case Report. 2018 , 50, 910-914 | 5 |
| 31 | Heavy Consumption of Alcohol is Not Associated With Worse Outcomes in Patients With Idiosyncratic Drug-induced Liver Injury Compared to Non-Drinkers. 2018 , 16, 722-729.e2 | 22 |
| 30 | Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors. 2018 , 625-650 | |
| 29 | Idiosyncratic Adverse Drug Reactions. 2018 , 681-716 | 3 |
| 28 | Genomewide Association Study Confirming the Association of with Susceptibility to Antituberculosis Drug-Induced Liver Injury in Thai Patients. 2019 , 63, | 13 |
| 27 | Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions. 2020 , 64, | 9 |
| 26 | Dendrobine attenuates isoniazid- and rifampicin-induced liver injury by inhibiting miR-295-5p. 2020 , 39, 1671-1680 | 7 |
| 25 | Chemotherapy of Tuberculosis. 2011 , 107-119 | 2 |
| 24 | Successful living donor liver transplantation of fulminant liver failure due to isoniazid prophylaxis. 2015 , 2015, | 1 |
| 23 | Side effects of antituberculosis therapy. 2004 , 169, 1168-9; author reply 1169 | 1 |
| 22 | The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1. 2014 , 9, e85905 | 36 |

| | | |
|----|--|-----|
| 21 | Alcohol consumption among men and women with tuberculosis in Tomsk, Russia. 2010 , 18, 132-8 | 14 |
| 20 | NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. 2007 , 13, 6003-8 | 46 |
| 19 | Incidence of Hepatotoxicity Due to Antitubercular Medicine and Assessment of Risk Factors, Zahedan, Iran. 2005 , 6, 44-47 | 1 |
| 18 | Antituberculosis drugs. 2006 , 321-326 | |
| 17 | Antihepatotoxic Effects of Boerhaavia diffusa L. on Antituberculosis Drug, Rifampicin Induced Liver Injury in Rats. 2008 , 3, 75-83 | 5 |
| 16 | ANTIBACTERIAL DRUGS. 2010 , 1-443 | |
| 15 | Drug-Induced Liver Injury in Children: A Structured Approach to Diagnosis and Management. 2014 , 371-388 | |
| 14 | Conclusions and Future Developments. 2014 , 447-470 | |
| 13 | Risk Factors and Pattern of Changes in Liver Enzymes Among the Patients With Anti-Tuberculosis Drug-Induced Hepatitis. 2015 , 2, | 1 |
| 12 | Rifampin, Dapsone, and Vancomycin. 2016 , 1-12 | |
| 11 | Rifampin, Dapsone, and Vancomycin. 2017 , 1299-1310 | |
| 10 | Drug-Induced Liver Disease. 2017 , 204-216 | |
| 9 | ADVERSE DRUG REACTIONS DUE TO ANTITUBERCULAR DRUGS DURING THE INITIAL PHASE OF THERAPY IN HOSPITALISED PATIENTS FOR TUBERCULOSIS IN SRI KRISHNA MEDICAL COLLEGE, MUZAFFARPUR, BIHAR. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2017 , 4, 1031-1036 | 0 |
| 8 | Tuberculosis of the Liver, Biliary Tract, and Pancreas. 439-482 | |
| 7 | Characteristics and risk factors for antituberculosis drug-induced liver injury in a cohort of patients with cirrhosis in a tertiary referral university teaching hospital in Thailand. <i>Asian Biomedicine</i> , 2019 , 12, 65-74 | 0.4 |
| 6 | Treatment of Drug-Sensitive Tuberculosis in Persons with HIV. 2019 , 181-202 | |
| 5 | Biochemical mechanisms of drug toxicity. 2022 , 267-302 | |
| 4 | A Study to Detect Liver Enzyme Dysfunction among Patients on First Line Anti-Tubercular Drugs from RNTCP during the Course of Anti-TB Treatment. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2020 , 9, 645-650 | 0.1 |

| | | | |
|---|---|-----|---|
| 3 | An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis. <i>Frontiers in Pharmacology</i> , 2021 , 12, 708522 | 5.6 | 1 |
| 2 | Evaluation of Risk Factors for Development of Anti-Tubercular Therapy Induced Hepatotoxicity: A Prospective Study. <i>Current Drug Safety</i> , 2020 , 15, 198-204 | 1.4 | 1 |
| 1 | Using an Artificial Intelligence Approach to Predict the Adverse Effects and Prognosis of Tuberculosis. 2023 , 13, 1075 | | 0 |